Rotura prematura de membranas en gestante afecta de mastocitosis cutánea / Premature rupture of membranes in pregnant women with cutaneous mastocytosis

La mastocitosis es una enfermedad poco frecuente, caracterizada por la proliferación de mastocitos. Los síntomas aparecen tras la exposición a factores desencadenantes, que generan una liberación de mediadores inflamatorios, pudiendo dar lugar a reacciones alérgicas e incluso a reacciones anafilácticas. Existen dos formas de presentación, la cutánea y la sistémica. Su relación con la gestación es poco conocida y hace plantearse aspectos sobre la seguridad tanto materna como fetal. Durante la gestación, esta entidad puede mejorar, empeorar o mantenerse estable y se ha relacionado con la amenaza de parto pretérmino, mientras que durante el parto es esencial el control del dolor y evitar aquellos fármacos que puedan desencadenar un brote. Además, los cambios hormonales acontecidos durante la gestación, parto y puerperio pueden favorecer la aparición de reacciones anafilácticas. Presentamos el caso de una gestante de 34 semanas de amenorrea, afecta de mastocitosis cutánea, que ingresó en nuestro servicio por rotura prematura de membranas, con lo que tuvimos que plantearnos cuál era el protocolo de actuación más adecuado a la patología que presentaba la paciente.

Mastocytosis is an uncommon disease characterized by the proliferation of mast cells. Symptoms appear after exposure to triggering factors resulting in mast cell mediator release, which can lead to anaphylactic reactions. There are two forms of presentation, cutaneous and systemic mastocytosis. There is limited information on the impact of this disorder on pregnancy and questions may arise about maternal and foetal safety. During pregnancy, this disease can improve, worsen, or remain stable and even be associated with preterm delivery. During labour pain control is important and drugs that can trigger an episode should be avoided. Furthermore, the hormonal changes that occur during pregnancy, childbirth and puerperium can lead to anaphylactic reactions. We present a pregnant woman at 34 weeks of amenorrhoea, affected by cutaneous mastocytosis, admitted in our hospital due to premature rupture of membranes. We had to consider the most appropriate protocol for our patient's pathology.

Empleo del análisis multimodal para el diagnóstico y seguimiento de un caso de retinopatía aguda zonal oculta externa (AZOOR) / Use of multimodal analysis in the diagnosis and follow-up of a case of Acute Zonal Occult Outer Retinopathy (AZOOR)

Con el objetivo de mostrar la utilidad del análisis multimodal en el diagnóstico y seguimiento de los pacientes con AZOOR, presentamos este caso clínico. Se trata de una paciente de 22 años que acudió a urgencias por fotopsias y escotoma paracentral en ojo izquierdo y que fue diagnosticada de AZOOR mediante la realización de diversas pruebas funcionales y estructurales. La evolución del caso fue hacia un empeoramiento estructural inicial seguido de la resolución casi completa de las lesiones objetivadas en las distintas pruebas realizadas con una mejoría sintomática evidente. El análisis multimodal de los casos de AZOOR permite un diagnóstico bastante preciso de esta enfermedad y su diferenciación de otras de aspecto similar como los síndromes de múltiples puntos blancos o la coroiditis multifocal (AU)

A clinical case is presented in order to show the usefulness of multimodal analysis in the diagnosis and monitoring of patients with Acute Zonal Occult Outer Retinopathy (AZOOR). A 22 year-old patient was seen in the emergency department complaining of photopsia and paracentral scotoma of the left eye. Several structural and functional tests were performed and the patient was diagnosed with AZOOR. The evolution of the case was towards an initial structural worsening, followed by the almost complete resolution of the lesions identified in the different tests carried out, with an obvious symptomatic improvement. Multimodal analysis of AZOOR cases allows a fairly accurate diagnosis of this condition, and its differentiation from others with a similar appearance, such as multiple white point syndromes, or multifocal choroiditis (AU)

Leiomioma ovárico primario en paciente posmenopáusica. Posibilidad dentro del diagnóstico diferencial de las neoplasias de ovario / Primary ovarian leiomyoma in a postmenopausal patient. Possibility within the differential diagnosis of ovarian neoplasms

El leiomioma primario de ovario es un tipo de tumor sólido muy infrecuente, detectándose como hallazgo incidental. El estudio preoperatorio por imagen es muy limitado por lo que es imprescindible el estudio anatomopatológico, que logre distinguirlo de otros tumores sólidos de ovario. Se presenta un caso atípico de leiomioma primario ovárico en una mujer posmenopáusica de 69 años, sometida a cirugía debido a una masa anexial izquierda de gran tamaño sospechosa de cistoadenocarcinoma en el estudio preoperatorio. El leiomioma ovárico primario debe ser considerado como posibilidad dentro del diagnóstico diferencial de las masas anexiales.(AU)

Primary ovarian leiomyoma is a rare, asymptomatic, ovarian tumour that is diagnosed incidentally. Preoperative study based on imaging is limited so an anatomopathological study is essential for diagnosis to differentiate it from other solid ovarian tumours. We hereby report an atypical case of a primary ovarian leiomyoma in a postmenopausal 69-year-old woman, diagnosed during surgery for suspected ovarian cancer. It is necessary to include primary ovarian leiomyoma within the differential diagnosis of the different adnexal tumours.(AU)

Use of multimodal analysis in the diagnosis and follow-up of a case of Acute Zonal Occult Outer Retinopathy (AZOOR).

A clinical case is presented in order to show the usefulness of multimodal analysis in the diagnosis and monitoring of patients with Acute Zonal Occult Outer Retinopathy (AZOOR). A 22 year-old patient was seen in the emergency department complaining of photopsia and paracentral scotoma of the left eye. Several structural and functional tests were performed and the patient was diagnosed with AZOOR. The evolution of the case was towards an initial structural worsening, followed by the almost complete resolution of the lesions identified in the different tests carried out, with an obvious symptomatic improvement. Multimodal analysis of AZOOR cases allows a fairly accurate diagnosis of this condition, and its differentiation from others with a similar appearance, such as multiple white point syndromes, or multifocal choroiditis.

Tumor de Brenner benigno asociado a tumor mucinoso borderline de ovario en paciente postmenopáusica / Benign Brenner tumour associated with a borderline mucinous tumour of the ovary in a post-menopausal patient

El tumor de Brenner es una neoplasia ovárica infrecuente de origen incierto, generalmente asintomática. Su diagnóstico es complejo, sin presentar patrones ecográficos específicos. Se ha asociado a tumores mucinosos con distinto potencial de malignidad, pudiendo encontrar componentes malignos o borderline que determinarán el tratamiento. Para su diagnóstico diferencial es esencial la realización de un estudio inmunohistoquímico, para objetivar el origen clonal del tumor de Brenner y de la estirpe mucinosa. Presentamos el caso de una mujer diagnosticada intraoperatoriamente de un tumor de Brenner asociado a un tumor mucinoso borderline de ovario, en el estudio definitivo posterior.(AU)

Brenner tumour is an uncommon neoplasm of the ovary of uncertain origin and often asymptomatic. Diagnostic is complex, without specific ultrasound patterns. It has been associated with mucinous tumours with different potential for malignancy, and it is possible to find malignant or borderline components that determine the treatment. For its differential diagnosis immunohistochemical study is essential, which shows, according to various studies, a clonal origin of Brenner and mucinous tumour. This is a case report of a Brenner tumour associated with a mucinous tumour, which in a definitive study showed to be associated with a borderline ovarian tumour component.(AU)

Use of multimodal analysis in the diagnosis and follow-up of a case of Acute Zonal Occult Outer Retinopathy (AZOOR). / Empleo del análisis multimodal para el diagnóstico y seguimiento de un caso de retinopatía aguda zonal oculta externa (AZOOR).

A clinical case is presented in order to show the usefulness of multimodal analysis in the diagnosis and monitoring of patients with Acute Zonal Occult Outer Retinopathy (AZOOR). A 22 year-old patient was seen in the emergency department complaining of photopsia and paracentral scotoma of the left eye. Several structural and functional tests were performed and the patient was diagnosed with AZOOR. The evolution of the case was towards an initial structural worsening, followed by the almost complete resolution of the lesions identified in the different tests carried out, with an obvious symptomatic improvement. Multimodal analysis of AZOOR cases allows a fairly accurate diagnosis of this condition, and its differentiation from others with a similar appearance, such as multiple white point syndromes, or multifocal choroiditis.

Monitorización farmacocinética de terapias biológicas en enfermedad inflamatoria intestinal / Pharmacokinetic monitoring of biological therapies in inflammatory bowel disease

Objective: To analyze the activity developed by a multidisciplinary team of pharmacists, digestive specialists and clinical analysts for the therapeutic drug monitoring (TDM) of anti-TNFa therapies in inflammatory bowel disease (IBD).Methods: A prospective observational study (January-December 2019) was conducted of referrals from digestive specialists to the Clinical Pharmacokinetics Unit (CPU) of our general hospital for the TDM of anti-TNFa drugs (infliximab/adalimumab) in adults with IBD. Serum anti-TNFa concentrations were quantified in our Clinical Analysis Laboratory using lateral flow chromatography. When concentrations were undetectable, the presence of anti-drug antibodies (ADAs) was analyzed.CPU recommendations were based on the correct interpretation of anti-TNFa concentrations, therapeutic algorithms, and populational pharmacokinetic models implemented using MW-Pharm++® software. Results: Referrals were received for 84 patients (81.0% with Crohn’s disease, 8.3% with ADAs) treated with infliximab (46.4%) or adalimumab (53.6%); 64.3% were also treated with concomitant immunomodulators (IMMs). Sixty-three referrals (75.0%) were for proactive monitoring (treatment optimization) and the remainder for reactive monitoring after therapeutic failure. Anti-TNFa concentrations were subtherapeutic in 36.9% of patients, therapeutic in 39.3%, and supratherapeutic in 23.8%. Subtherapeutic/undetectable concentrations were significantly more frequent (p≤0.004) in patients treated with infliximab versus adalimumab (64.1% vs.. 13.3%) and in concomitant IMM non-adherents versus adherents (85.7% vs. 25.5%). Conclusions: Anti-TNFa TDM is frequently proactive in patients with IBD. The wide variability in anti-TNFa concentrations is in part explained by the type of anti-TNFa drug and adherence to IMM. (AU)

Objetivo: Analizar la actividad desarrollada por un equipo multidisciplinar formado por farmacéuticos, digestólogos y analistas clínicos para la monitorización farmacocinética (TDM) de terapias anti-TNFa en la enfermedad inflamatoria intestinal (EII).Métodos: Estudio observacional prospectivo (enero–diciembre 2019) de las interconsultas de TDM de anti-TNFa (infliximab/adalimumab) en pacientes adultos con EII, solicitadas por digestólogos a la Unidad de Farmacocinética Clínica (UFC) del Servicio de Farmacia de un hospital general. Las concentraciones séricas (Cs) de anti-TNFa fueron cuantificadas en el Laboratorio de Análisis Clínicos mediante cromatografía de flujo lateral. Cuando las Cs fueron indetectables, se analizó la presencia de anticuerpos anti-fármaco (AAF).La UFC realizó recomendaciones en base a la correcta interpretación de las Cs de anti-TNFa, algoritmos terapéuticos y modelos farmacocinéticos poblacionales implementados en el programa informático de ajuste bayesiano MW-Pharm++®. Resultados: Se solicitaron interconsultas para 84 pacientes (81,0% enfermedad de Crohn, 8,3% AAF positivos) con infliximab (46,4%) ó adalimumab (53,6%). 64,3% recibía otros inmunomoduladores (IMM) concomitantes. 63 interconsultas (75,0%) se relacionaron con monitorización ‘pro-activa’ (optimizar tratamiento); el resto fueron ‘re-activas’ a fallo terapéutico. Se observaron Cs de anti-TNFa subterapéuticas en 36,9% de pacientes, terapéuticas en 39,3% y supraterapéuticas en 23,8%. Las Cs subterapéuticas/indetectables fueron significativamente (p≤0,004) más frecuentes en pacientes tratados con infliximab versus adalimumab (64,1% vs. 13,3%); y en ‘no-adherentes’ versus ‘sí-adherentes’ al IMM concomitante (85,7% vs. 25,5%). Conclusiones: En estos pacientes, la TDM de anti-TNFa es frecuentemente ‘pro-activa’. Existe gran variabilidad en las Cs de anti-TNFa, explicada en parte por el fármaco anti-TNFa y la adherencia al IMM. (AU)

Faco-esclerectomía profunda no perforante como tratamiento de la hipertensión ocular secundaria al implante intravítreo de dexametasona / Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant

OBJETIVO: Evaluar las características y la evolución de los pacientes que requirieron cirugía filtrante de glaucoma (esclerectomía profunda no perforante) para controlar la hipertensión ocular (HTO) secundaria al implante intravítreo de 0,7 mg de dexametasona (Ozurdex(R)). MÉTODOS: Serie de casos observacional retrospectiva de pacientes tratados mediante Ozurdex(R) en un hospital terciario universitario entre mayo 2011 y abril 2016. RESULTADOS: El 1,10% (4/363) de los pacientes tratados con Ozurdex(R) requirieron faco-esclerectomía profunda no perforante (FEPNP) para controlar la HTO secundaria refractaria a tratamiento médico hipotensor. Los 4 casos comenzaron el tratamiento tópico hipotensor o aumentaron su tratamiento hipotensor previo desde el primer implante intravítreo de Ozurdex(R). Todos los casos habían recibido 3 o más inyecciones de Ozurdex(R) antes de que se requiriera la realización de la FEPNP para el control de la PIO. Tras el tratamiento quirúrgico, en todos los casos se alcanzó una PIO óptima sin necesidad de tratamiento tópico adicional. Dos pacientes requirieron retratamiento con nuevas inyecciones de Ozurdex(R) después de la FEPNP, manteniéndose la PIO dentro de los límites normales sin necesidad de tratamiento. CONCLUSIONES: Esta es la primera serie de casos que aporta información acerca de los favorables resultados de la FEPNP como tratamiento de la HTO secundaria a implante intravítreo de Ozurdex(R). Los 4 casos presentan una PIO controlada sin tratamiento tras la cirugía. El retratamiento con Ozurdex(R) en aquellos pacientes que se han sometido a FEPNP es posible, manteniéndose un buen control de la PIO

PURPOSE: To evaluate the characteristics and progression of patients treated with a 0.7 mg dexamethasone intravitreal implant (Ozurdex(R)) and required glaucoma filtering surgery (phaco-non-penetrating deep sclerectomy) to control ocular hypertension (OHT). METHODS: A retrospective observational study including patients treated with Ozurdex(R) in a tertiary-care university hospital from May 2011 to April 2016. RESULTS: In five years of follow-up, 1.10% (4/363) of patients treated with 0.7 mg dexamethasone intravitreal implant required phaco-non-penetrating deep sclerectomy (PNPDS) to control OHT refractory to topical treatment. All four patients started or increased previous antihypertensive topical treatment since the first dexamethasone intravitreal implant. Three or more dexamethasone intravitreal implants were injected in the four cases before intraocular pressure (IOP) became uncontrolled and PNPDS was performed. All four patients have a successfully controlled IOP without treatment after PNPDS. Two patients required additional treatment with dexamethasone intravitreal implants after PNPDS, maintaining IOP under control without treatment. CONCLUSIONS: To the best of our knowledge, this is the first study describing the successful results of PNPDS in OHT secondary to dexamethasone intravitreal implant. All four patients have achieved controlled IOP without treatment. Re-treatment with dexamethasone intravitreal implant in those patients who underwent PNPDS is also possible, and IOP remains controlled

Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant. / Faco-esclerectomía profunda no perforante como tratamiento de la hipertensión ocular secundaria al implante intravítreo de dexametasona.

PURPOSE: To evaluate the characteristics and progression of patients treated with a 0.7mg dexamethasone intravitreal implant (Ozurdex®) and required glaucoma filtering surgery (phaco-non-penetrating deep sclerectomy) to control ocular hypertension (OHT). METHODS: A retrospective observational study including patients treated with Ozurdex® in a tertiary-care university hospital from May 2011 to April 2016. RESULTS: In five years of follow-up, 1.10% (4/363) of patients treated with 0.7mg dexamethasone intravitreal implant required phaco-non-penetrating deep sclerectomy (PNPDS) to control OHT refractory to topical treatment. All four patients started or increased previous antihypertensive topical treatment since the first dexamethasone intravitreal implant. Three or more dexamethasone intravitreal implants were injected in the four cases before intraocular pressure (IOP) became uncontrolled and PNPDS was performed. All four patients have a successfully controlled IOP without treatment after PNPDS. Two patients required additional treatment with dexamethasone intravitreal implants after PNPDS, maintaining IOP under control without treatment. CONCLUSIONS: To the best of our knowledge, this is the first study describing the successful results of PNPDS in OHT secondary to dexamethasone intravitreal implant. All four patients have achieved controlled IOP without treatment. Re-treatment with dexamethasone intravitreal implant in those patients who underwent PNPDS is also possible, and IOP remains controlled.

[Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case]. / Bevacizumab intravítreo seguido de láser focal en el edema macular diabético difuso de progresión reciente. Caso clínico.

CASE REPORT: We report the case of a 48-year-old man with diffuse diabetic macular edema of recent progression treated with two consecutive intravitreal injections of bevacizumab followed by focal laser therapy, with good anatomic and functional response. DISCUSSION: Diffuse diabetic macular edema is difficult to manage and frequently requires multiple therapies. We propose the use of bevacizumab as a strategy to reduce diffuse macular edema, facilitating the application of laser therapy.

Bevacizumab intravítreo seguido de láser focal en el edema macular diabético difuso de progresión reciente. Caso clínico / Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case

Caso clínico: Se presenta el caso de un varón de 48años de edad con edema macular diabético (EMD)difuso en su ojo derecho (OD) de reciente progresión,que es tratado con dos inyecciones intravítreasconsecutivas de bevacizumab seguido de láserfocal, mostrando buena respuesta funcional y anatómica.Discusión: El EMD difuso es de difícil manejo ycon frecuencia precisa de multiterapias para su control.Proponemos el uso de bevacizumab intravítreocomo coadyuvante para reducir el EMD difuso deprogresión reciente, y facilitar la aplicación de fotocoagulacióncon láser(AU)

Case report:We report the case of a 48-year-old manwith diffuse diabetic macular edema of recent progressiontreated with two consecutive intravitrealinjections of bevacizumab followed by focal laser therapy,with good anatomic and functional response.Discussion: Diffuse diabetic macular edema is difficultto manage and frequently requires multipletherapies. We propose the use of bevacizumab as astrategy to reduce diffuse macular edema, facilitatingthe application of laser therapy(AU)

[Conservative surgical management of a post-traumatic iris cyst]. / Tratamiento quirúrgico conservador en un caso de quiste de iris postraumático.

CASE REPORT: A 32-year-old man with recent visual loss in his right eye, was found to have an iris cyst involving about 50% of the anterior chamber. He had been treated three years previously for a penetrating injury to that eye. The cyst was treated by aspiration, viscodissection and ab-externo photocoagulation, with this achieving a rapid recovery of vision and good anatomic results. At the six month follow-up visit the visual acuity remains stable with no signs of recurrence of the cyst. DISCUSSION: Conservative surgical treatment consisting of aspiration, viscodissection and photocoagulation appears to be an effective strategy to manage secondary anterior chamber cysts, achieving good anatomic and functional results.

Tratamiento quirúrgico conservador en un caso de quiste de iris postraumático / Conservative surgical management of a posttraumatic iris cyst

Caso clínico: Varón de 32 años aquejado de pérdida visual en ojo derecho (OD) secundario a un quiste que ocupa la mitad de la cámara anterior, diagnosticado clínicamente de quiste secundario epitelial de iris. Tres años antes había sufrido un traumatismo penetrante. Se realiza aspiración con aguja, viscodisección y fotocoagulación ab externo, logrando una rápida recuperación visual sin secuelas funcionales ni anatómicas. A los seis meses la agudeza visual permanece estable sin recidiva de la lesión. Discusión: El manejo quirúrgico conservador mediante aspiración y fotocoagulación en este caso fue eficaz y seguro en el tratamiento del quiste epitelial adquirido de iris

Case report: A 32-year-old man with recent visual loss in his right eye, was found to have an iris cyst involving about 50% of the anterior chamber. He had been treated three years previously for a penetrating injury to that eye. The cyst was treated by aspiration, viscodissection and ab-externo photocoagulation, with this achieving a rapid recovery of vision and good anatomic results. At the six month follow-up visit the visual acuity remains stable with no signs of recurrence of the cyst. Discussion: Conservative surgical treatment consisting of aspiration, viscodissection and photocoagulation appears to be an effective strategy to manage secondary anterior chamber cysts, achieving good anatomic and functional results

[Short- and medium-term intraocular pressure lowering effects of combined phacoemulsification and non-penetrating deep sclerectomy without scleral implant or antifibrotics]. / Control tensional a corto y medio plazo de facoesclerectomía profunda no perforante sin implante escleral ni antimetabolito.

PURPOSE: To examine the short- and medium-term intraocular pressure (IOP) lowering effects of combined phacoemulsification and non-penetrating deep sclerectomy without the use of scleral implant or antifibrotics in open-angle glaucoma (primary and pseudoexfoliative) and coexisting cataract in eyes with no known risk factors for bleb failure. METHODS: Retrospective study of 15 eyes of 12 patients with medically uncontrolled open-angle glaucoma or open-angle glaucoma treated with two or more drugs and coexisting cataract with no known risk factors for glaucoma surgery failure. All patients received combined phacoemulsification and non-penetrating deep sclerectomy without scleral implant or antifibrotics performed by the same surgeon. Nd-YAG perforation of the trabeculodescemetic membrane and/or needling with mitomycin-C was performed postoperatively for IOP control. Main outcome measures were postoperative IOP, percentage of eyes with IOP < 17 mmHg, complications and final visual acuity (VA). Median follow-up was 12.0 months (SD: 0.6) and ranged from 1 to 30 months. RESULTS: Mean preoperative IOP with medical treatment was 21.80 mmHg (SD: 5.14) and decreased to 14.42 mmHg (SD: 2.15) at 12-month visit. Mean antiglaucoma medication preoperative was 1.93 (SD: 0.70) and was reduced to 0.13 (DE: 0.35) postoperative. At 12-month visit, 80% had an IOP lower than 17 mmHg with a mean VA gain of 2.50 Snellen lines. Conjuntival wound leakage was the most frequent complication (20%; 3/15). CONCLUSIONS: Primary combined phacoemulsification and non-penetrating deep sclerectomy without collagen implant or antifibrotics in primary open-angle glaucoma with coexisting cataract, significantly lowers IOP in the short- and medium term in low-risk cases for glaucoma surgery failure, allowing for rapid visual improvement with a low complication rate.

Control tensional a corto y medio plazo de facoesclerectomía profunda no perforante sin implante escleral ni antimetabolito / Short- and medium-term intraocular pressure lowering effects of combined phacoemulsification and non-penetrating deep sclerectomy without scleral implant or antifibrotics

Objetivo: Evaluar los resultados sobre la presiónintraocular (PIO) a corto y medio plazo de la cirugíacombinada de facoemulsificación y esclerectomíaprofunda no perforante (FEPNP) sin implanteescleral ni antimetabolito en el glaucoma de ánguloabierto, primario y pseudoexfoliativo (GAA).Métodos: Estudio retrospectivo de quince ojos dedoce pacientes con GAA mal controlado farmacológicamentecon catarata o que, estando bien controladoscon medicación, precisaban ser intervenidosde catarata. Todos fueron intervenidos deFEPNP por un mismo cirujano. La PIO postoperatoriapor encima del objetivo preestablecido fue tratadamediante punción de membrana trabéculo-desceméticacon láser Nd-YAG y/o manipulación de laampolla de filtración con mitomicina C. Los principalesparámetros evaluados fueron: PIO pre y postoperatoria,porcentaje de ojos con PIO < 17mmHg,reducción en número de fármacos hipotensores,incidencia de complicaciones y agudeza visual(AV). El seguimiento mediano fue de 12,00 meses(DE: 0,6) con un rango de 1 a 30 meses.Resultados: La PIO preoperatoria media era 21,80(DE: 5,14) y descendió a 14,42 (DE: 2,15) a los 12 meses. La media de fármacos hipotensores empleadosen el preoperatorio fue 1,97 (DE: 0,70) y descendióa 0,13 (DE: 0,35) tras cirugía. A los 12meses, el 80% mantienen PIO< 17 mmHg con unaganancia media de AV de 2,50 (DE: 1,91) líneas deSnellen. La complicación postoperatoria más frecuentefue la filtración a través del colgajo conjuntival,ocurrida en tres de los quince ojos (20%).Conclusiones: La FEPNP sin implante ni antimetabolitoes una opción efectiva en el manejo del GAAcon catarata en ojos sin factores de riesgo de fracasode cirugía filtrante. Esta técnica reduce significativamentela PIO así como la necesidad de fármacosantiglaucomatosos a corto y medio plazo permitiendouna rápida rehabilitación visual con escasascomplicaciones

Purpose: To examine the short- and medium-term intraocular pressure (IOP) lowering effects of combined phacoemulsification and non-penetrating deep sclerectomy without the use of scleral implant or antifibrotics in open-angle glaucoma (primary and pseudoexfoliative) and coexisting cataract in eyes with no known risk factors for bleb failure. Methods: Retrospective study of 15 eyes of 12 patients with medically uncontrolled open-angle glaucoma or open-angle glaucoma treated with two or more drugs and coexisting cataract with no known risk factors for glaucoma surgery failure. All patients received combined phacoemulsification and nonpenetrating deep sclerectomy without scleral implant or antifibrotics performed by the same surgeon. Nd- YAG perforation of the trabeculodescemetic membrane and/or needling with mitomycin-C was performed postoperatively for IOP control. Main outcome measures were postoperative IOP, percentage of eyes with IOP <17mmHg, complications and final visual acuity (VA). Median follow-up was 12.0 months (SD: 0.6) and ranged from 1 to 30 months. Results: Mean preoperative IOP with medical treatment was 21.80 mmHg (SD: 5.14) and decreased to 14.42 mmHg (SD: 2.15) at 12-month visit. Mean antiglaucoma medication preoperative was 1.93 (SD: 0.70) and was reduced to 0.13 (DE: 0.35) postoperative. At 12-month visit, 80% had an IOP lower than 17 mmHg with a mean VA gain of 2.50 Snellen lines. Conjuntival wound leakage was the most frequent complication (20%; 3/15). Conclusions: Primary combined phacoemulsification and non-penetrating deep sclerectomy without collagen implant or antifibrotics in primary openangle glaucoma with coexisting cataract, significantly lowers IOP in the short- and medium term in low-risk cases for glaucoma surgery failure, allowing for rapid visual improvement with a low complication rate

[Panuveitis as a possible ophthalmic complication of Kikuchi-Fujimoto disease]. / Panuveítis como posible manifestación oftalmológica de la enfermedad de Kikuchi-Fujimoto.

CLINICAL CASE: A 37 year old female with histologically proven Kikuchi-Fujimoto disease is presented. She developed panuveitis, vasculitis and subretinal macular infiltrate, probably as a recurrence of the disease. Immunosuppressive treatment (methotrexate) was initiated in the absence of response to systemic steroid therapy and threat to vision owing to macular involvement. DISCUSSION: Ophthalmic complications of Kikuchi-Fujimoto disease are unusual. We discuss differential diagnosis and emphasize the aggresiveness of our case.

Panuveítis como posible manifestación oftalmológica de la enfermedad de Kikuchi-Fujimoto / Panuveitis as a posible ophthalmic complication of Kikuchi-Fujimoto disease

Caso clínico: Se presenta el caso de una mujer de 37 años con enfermedad de Kikuchi-Fujimoto confirmada histológicamente, con panuveítis, vasculitis y edema macular con infiltrados subretinianos, posiblemente en el seno de una recidiva de la enfermedad, con buena respuesta al tratamiento inmunosupresor (metotrexate) que fue instaurado ante la falta de respuesta al tratamiento corticoideo sistémico y la importante amenaza visual por la afectación macular.Discusión: Las manifestaciones oftalmológicas de la enfermedad de Kikuchi-Fujimoto son excepcionales, discutimos el posible diagnóstico diferencial, destacando la agresividad de nuestro caso

Clinical case: A 37 year old female with histologically proven Kikuchi-Fujimoto disease is presented. She developed panuveitis, vasculitis and subretinal macular infiltrate, probably as a recurrence of the disease. Immunosuppressive treatment (methotrexate) was initiated in the absence of response to systemic steroid therapy and threat to vision owing to macular involvement.Discussion: Ophthalmic complications of Kikuchi-Fujimoto disease are unusual. We discuss differential diagnosis and emphasize the aggresiveness of our case

[Tuberculous meningitis. One case: ophthalmic complications]. / Meningitis tuberculosa. Un caso: complicaciones oftalmológicas.

CASE REPORT: An 18 year old female suffering from tuberculous meningitis with bilateral amaurosis, ophthalmoplegia, other cranial nerve palsies and loss of consciousness, is presented. DISCUSSION: Tuberculous meningitis is a rare cause of basal arachnoiditis with a bad prognosis. Possible causes of visual acuity loss and ophthalmoplegia are discussed and a favourable outcome without sequelae is noteworthy in our case.

Meningitis tuberculosa. Un caso: complicaciones oftalmológicas / Tuberculous meningitis. One case: Ophthalmic complications

Caso clínico: Presentamos una mujer de 18 años afecta de meningitis tuberculosa con amaurosis bilateral y oftalmoplegia completa, además de pérdida de conciencia y parálisis de otros pares craneales. Discusión: La meningitis tuberculosa es una causa infrecuente de aracnoiditis basal con pronóstico infausto. Se valoran las posibles causas de la pérdida de agudeza visual y la afectación oculomotora , y se destaca la evolución favorable del caso sin secuelas(AU)

Case Report: An 18 year old female suffering from tuberculous meningitis with bilateral amaurosis, ophthalmoplegia, other cranial nerve palsies and loss of consciousness, is presented. Discussion: Tuberculous meningitis is a rare cause of basal arachnoiditis with a bad prognosis. Possible causes of visual acuity loss and ophthalmoplegia are discussed and a favourable outcome without sequelae is noteworthy in our case(AU)